

Our Vision

Empowered by independence, people with spinal cord injuries will enjoy life in the ways that matters to them

Company Profile

ONWARD® Medical is a medical technology company creating innovative therapies to restore movement, function, and independence in people with spinal cord injuries (SCI)

ONWARD Medical's work builds on more than a decade of basic science, pre-clinical, and clinical research conducted at the world's leading neuroscience laboratories

Investment Highlights

Differentiated technology

- Ten FDA Breakthrough Device Designation awards
- Compelling body of scientific evidence published, and clinical evidence published in top-tier journals like *Nature* and *NEJM*
- Leaders in Brain Computer Interface (BCI) technology with 7 humans implanted
- First-mover advantage with IP portfolio of 150+ issued patents¹

Favorable go-to-market

- >80 US clinics penetrated in first year on the market
- Commercially available across US, EU, UK, and Switzerland for clinic and home use
- High level of awareness among clinical and patient communities
- Highly concentrated customer base of SCI rehabilitation clinics across US and Europe

Corporate strength

- Experienced global management team with proven track record
- Strong shareholder base and access to capital; strategic investments from Ottobock and Christopher & Dana Reeve Foundation

¹ Patent figures as of end of 1H 2025, number excludes EP country validations; company has 300+ issued patents including EP country validations

Technology Portfolio



ARC EX

External Stimulation ●●●●●

Commercial

First indication: Hand sensation & strength after SCI

Pivotal trial results published in 2024 in *Nature Medicine*

Commercially available in the US, EU, UK, and Switzerland



ARC IM

Implanted Stimulation ●●●●●

Pivotal trial ongoing

First indication: Blood pressure instability after SCI

Global pivotal trial ongoing, Empower BP (up to 22 sites)

Clinical feasibility studies for mobility, blood pressure instability, and urinary incontinence ongoing in SCI and Parkinson's disease



ARC TBM

Thought-Driven Movement ●●●●●

Ongoing clinical feasibility studies

First indication: Upper limb or mobility after SCI (TBD)

Clinical feasibility studies for mobility and upper limb function ongoing (7 implants announced to date) in SCI

Additional implants in SCI and stroke expected

▶ [Watch the video](#)

●●●●● Pre-Clinical

●●●●● Human PoC

●●●●● Clinical Feasibility

●●●●● Pivotal

●●●●● Commercial

Note: ARCSM and ARCTM are investigational devices, not available for commercial use. The ONWARD[®] Medical ARCSM System is cleared for use in the United States and Europe. SCI = Spinal Cord Injury.

Upcoming Milestones & News Flow

ARC^{EX}

First commercial clinic sale EU

(Hand sensation & strength)

COMPLETED

ARC^{EX}

First commercial home use sale US

(Hand sensation & strength)

COMPLETED

ARC^{EX}

First commercial clinic sale ROW

(Hand sensation & strength)

COMPLETED

ARC^{EX}

First commercial home use sale EU

(Hand sensation & strength)

ARC^{IM}

First participant enrollment

Empower BP pivotal study (Blood pressure)

COMPLETED

ARC^{IM}

Additional implants

(Parkinson's disease)

COMPLETED

ARC^{IM}

Additional implants (Mobility)

COMPLETED

ARC^{IM}

First-in-human² (Bladder)

ARC^{IM}

Top line interim analysis

Empower BP pivotal study (Blood pressure)

ARC^{BCI}

Additional implants³

(SCI mobility)

COMPLETED

ARC^{BCI}

Additional implants³

(SCI upper limb)

ARC^{BCI}

Additional implants³

(Stroke upper limb)

Note: All platforms and therapies are for investigational use only

¹Funded by Michael J. Fox Foundation for Parkinson's Research grant

²Funded by Christopher & Dana Reeve Foundation grant

³Funded by European Innovation Council and Christopher & Dana Reeve Foundation grants

Key Financial Information

- Strong shareholder base and access to equity capital and debt financing
- Listed on Euronext Brussels, Amsterdam and Paris (Euronext: ONWD); US OTCQX = ONWRY
- Research coverage and Buy ratings by Stifel, KBC Securities, Degroof Petercam, Kepler Cheuvreux, and BNP Paribas
- Cash position 30 June 2026 - €81.5M net cash⁴

Financial Calendar 2026

⁴Net cash is defined as the sum of cash and cash equivalents and fixed term deposits included in the current assets as included in consolidated statement of financial position in the Financial Statements

About Us

Seasoned Management Team

Dave Marver Chief Executive Officer

Rob Ten Hoedt Chairman of the Board

Ali Kiboro Chief Financial Officer

Sean Sciara Chief Commercial Officer

Shari O'Quinn Chief Clinical, Regulatory & Quality Officer

Julien Camisani VP Engineering

Bob Odell VP Operations

International Presence

~140 FTEs collectively working to create therapies that change lives

Headquartered in the Netherlands, with a science and engineering hub in Switzerland, and a US office in Boston, Massachusetts

Key Partners

- Research partnership with .NeuroRestore, a collaboration between the Swiss Federal Institute of Technology (EPFL) and Lausanne University Hospital (CHUV)
- Christopher and Dana Reeve Foundation is a strategic investor and grantor; Michael J. Fox Foundation is a grantor
- Licensing agreements with CEA-Clinatex, Caltech, the University of California, and other leading neuroscience research institutions

This investor fact sheet (the "Fact Sheet") is provided by ONWARD Medical NV (the "Company") for informational purposes only. The information contained herein does not purport to be all-inclusive and neither the Company nor any of its or their control persons, officers, directors, employees or representatives makes any representation or warranty, express or implied, as to the accuracy, completeness or reliability of the information contained in this Fact Sheet.

This Fact Sheet contains forward-looking statements. These forward-looking statements include, but are not limited to, statements regarding the Company's intent, belief or current expectations; future events; future opportunities for the Company; future planned products and services; business strategy and plans; objectives of management for future operations of the Company; market size and growth opportunities; competitive position; technological and market trends; and other statements that are not historical facts. Forward-looking statements generally are accompanied by words such as "believe," "may," "will," "estimate," "continue," "anticipate," "intend," "expect," "should," "could," "would," "plan," "predict," "potential," "seem," "seek," "future," "outlook," "suggests," "targets," "projects," "forecast" and similar expressions that predict or indicate future events or trends or that are not statements of historical matters.

These forward-looking statements are based on the current expectations, beliefs and assumptions of the Company's management and on information currently available to management and are not predictions of actual performance or further results. Forward-looking statements are subject to risks and uncertainties, and actual results may differ materially from those expressed or implied in the forward-looking statements. Forward-looking statements speak only as of the date they are made, and the Company assumes no duty to and does not undertake to update forward-looking statements. Actual results could differ materially from those anticipated in forward-looking statements and future results could differ materially from historical performance.

This Fact Sheet is for informational purposes only and does not constitute, or form a part of, an offer to sell or the solicitation of an offer to sell or an offer to buy or the solicitation of an offer to buy any securities, and there shall be no sale of securities, in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction.

